Rheumatoid Arthritis

A new study of AbbVie’s original JAK1-selective inhibitor indicates that it outdoes adalimumab without sacrificing safety in rheumatoid arthritis treatment.

Patients with rheumatoid arthritis receiving combination treatment were more likely to reach ACR20, ACR50, and ACR70 than those receiving methotrexate monotherapy.

Assorted trials and a long-term exposure study of 3770 patients with rheumatoid arthritis further demonstrate baricitinib’s previously recorded safety profile.

Switching from a biologic to a biosimilar did not affect safety or efficacy in a clinical trial of a rheumatoid arthritis biosimilar for etanercept (Enbrel, Amgen), shows a new study.

A second study published in May on the safety and efficacy of biosimilars, shows that switching rheumatoid arthritis patients from etanercept (Enbrel, Amgen) to its biosimilar etanercept-szzs (Erelzi, Sandoz), does not affect efficacy, safety or immunogenicity of etanercept.

Getting more exercise can reduce a woman’s risk of developing rheumatoid arthritis, according to new research.

Serious infections are low, but herpes zoster surpasses expectations, review article shows.

The JAK inhibitor tofacitinib presents a comparably low risk of venous thromboembolism to rheumatoid arthritis patients as do TNFi inhibitors, according to a new study.

Tofacitinib 5 mg or 10 mg twice daily with methotrexate can sustain improvements for 24 months, one study shows.

Baricitinib treatment does not increase the risk for cardiovascular problems in patients with rheumatoid arthritis, according to new research.

Rheumatoid arthritis patients taking tofacitinib could face some increased risks for significant cardiovascular events, depending upon their underlying characteristics, according to the results of a new study.

Rheumatoid arthritis patients and rheumatology providers share many of the same concerns over obstacles that make it harder to reach treat-to-target goals, according to a new study.

The study also found that the overall rate of cardiovascular events was low in the study population, indicating that statins aren’t required for all RA patients.

An editorial in today's issue of Rheumatology makes a strong case for trying subcutaneous methotrexate first before a biologic.

Electronic health records data can be used to create forecast models of disease outcomes in rheumatoid arthritis patients, according to new research.

Increased competition in the pharmaceutical market does not necessarily translate into price reductions. "Our findings illustrate a market failure contributing to the rising costs of prescription drugs," researchers write in JAMA Internal Medicine.

The impact of omega-3 fatty acids (FA) on systemic inflammatory responses has been demonstrated in a number of dietary and epidemiologic studies. A recent editorial in Joint Bone Spine by Olfa Saidane1 and colleagues suggests a prophylactic role of Omega-3 FAs in the possible prevention of inflammatory diseases such as rheumatoid arthritis (RA).

A recent study published in Medicine highlights the top 100 articles focused on rheumatoid arthritis that have revealed the most data. Learn more in this article.

The JAK1 inhibitor will be considered as a marketed once-daily therapy for moderate to severe RA in the second half of this year.

Despite years of research that show omega-3 fatty acids from specific fish species can improve rheumatoid arthritis (RA) symptoms and even protect at-risk patients from developing RA, a new study of 3,863,909 person-years published in BMC Musculoskeletal Disorders finds no benefit.

The benefits of exercise to combat the effects of musculoskeletal conditions have been well-documented. Take this quiz to test your knowledge of sports and exercise medicine in rheumatology.

An assay designed to track TNF counts in recently-treated RA patients found that early reduction of the protein could indicate future problems for the patient.

ABP 798, a biosimilar candidate for rituximab, met pharmacokinetic, efficacy, and safety endpoints in a trial among participants with rheumatoid arthritis.

Madelaine A. Feldman, MD, FACR, shares about the current standard treatment rheumatoid arthritis and the hurdles to providing optimal treatment.

The investigators used FDG PET-CT to detect myocardial inflammation in RA patients without clinical heart failure.